RedShift BioAnalytics
Burlington
About RedShift BioAnalytics
RedShiftBio provides an infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. It has developed a Microfluidic Modulation Spectroscopy (MMS) platform in response to a customer’s request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications. They started a new and developed MMS from the ground up specifically with the protein scientist in mind. The company was founded in 2005 and is headquartered in Burlington, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $76.7M
- Last round: Series Unknown (Jun 2025)
- Website: redshiftbio.com
- Phone: 781.345.7300
Industries & Categories
Biotechnology, Electronics, Enterprise Software, Life Science, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/redshift-bioanalytics-7583 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.